Comments on IPO project
Rémi Delansorne
CEO
Paris, November 19, 2007 — Hybrigenics, a biotech company specialized in developing drugs to treat cancer, is going public. Hybrigenics CEO Rémi Delansorne comments on the IPO process and outlook.
– Web site: www.hybrigenics.com
